A team led by KineMed has shown that measuring the kinetics of CNS proteins in cerebrospinal fluid could help diagnose Parkinson's disease and amyotrophic lateral sclerosis. The company is now exploring the utility of the approach to diagnose multiple neurodegenerative diseases and to monitor treatment responses.